Ghisallo Capital Management LLC Takes Position in Maze Therapeutics, Inc. $MAZE

Key Points

• Ghisallo Capital Management LLC acquired a new position in Maze Therapeutics, purchasing 30,000 shares valued at approximately $330,000 during the first quarter.
• Several hedge funds have also increased their stakes in Maze Therapeutics, with notable acquisitions including Bank of New York Mellon Corp buying a position worth about $190,000.
• Maze Therapeutics reported earnings per share of ($0.77) for the latest quarter, surpassing analysts' consensus estimates of ($0.79) by $0.02.

Ghisallo Capital Management LLC bought a new stake in Maze Therapeutics, Inc. (NASDAQ:MAZE - Free Report) during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 30,000 shares of the company's stock, valued at approximately $330,000. Ghisallo Capital Management LLC owned 0.07% of Maze Therapeutics at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. Alphabet Inc. acquired a new position in shares of Maze Therapeutics in the first quarter valued at approximately $26,561,000. Bank of New York Mellon Corp acquired a new position in Maze Therapeutics during the first quarter worth $190,000. General Catalyst Group Management LLC acquired a new position in Maze Therapeutics during the first quarter worth $11,405,000. TRV GP V LLC acquired a new position in Maze Therapeutics during the first quarter worth $10,468,000. Finally, Harvard Management Co. Inc. acquired a new position in Maze Therapeutics during the first quarter worth $7,019,000.

Maze Therapeutics Stock Down 1.0%

Shares of NASDAQ:MAZE traded down $0.15 on Thursday, hitting $15.04. The company had a trading volume of 354,893 shares, compared to its average volume of 218,685. Maze Therapeutics, Inc. has a 52-week low of $6.71 and a 52-week high of $19.19. The business has a 50 day moving average of $14.43 and a 200 day moving average of $11.98.

Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last issued its quarterly earnings data on Tuesday, August 12th. The company reported ($0.77) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.79) by $0.02.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on MAZE. Wedbush began coverage on Maze Therapeutics in a report on Tuesday, July 8th. They set an "outperform" rating and a $17.00 price objective on the stock. BTIG Research initiated coverage on Maze Therapeutics in a research report on Tuesday. They set a "buy" rating and a $30.00 target price on the stock. Wall Street Zen upgraded Maze Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, August 16th. Finally, HC Wainwright initiated coverage on Maze Therapeutics in a research report on Wednesday, July 23rd. They set a "buy" rating and a $34.00 target price on the stock. Two research analysts have rated the stock with a Strong Buy rating and six have assigned a Buy rating to the stock. Based on data from MarketBeat, the company has an average rating of "Buy" and an average target price of $26.33.

Maze Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.